Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy.
暂无分享,去创建一个
B. Clarkson | J. Gaynor | D. Merke | J. Caravelli | J. Yahalom | J. Myers | D. Straus | D. Chapman | D. Straus | J. Myers
[1] Z. Fuks,et al. Total lymphoid irradiation, high-dose chemotherapy and autologous bone marrow transplantation for chemotherapy-resistant Hodgkin's disease. , 1989, International journal of radiation oncology, biology, physics.
[2] J. Armitage,et al. Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] M Tubiana,et al. Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin's disease. The EORTC Lymphoma Group controlled clinical trials: 1964-1987. , 1989, Blood.
[4] M. Maschio,et al. Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage I-II Hodgkin's disease. , 1988, Journal of the National Cancer Institute.
[5] N. Nissen,et al. Prognostic factors in Hodgkin's disease stage IV , 1988, European journal of haematology.
[6] M. Socinski,et al. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. , 1988, The New England journal of medicine.
[7] B. Shank,et al. Autologous bone marrow transplantation for patients with poor-prognosis lymphoma. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] J. Gabrilove,et al. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. , 1988, The New England journal of medicine.
[9] M. Andreeff,et al. A cause-specific hazard rate analysis of prognostic factors among 199 adults with acute lymphoblastic leukemia: the Memorial Hospital experience since 1969. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] J. Bertino,et al. Combined modality therapy for advanced Hodgkin's disease: 15-year follow-up data. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] L. Nadler,et al. Autologous bone marrow transplantation in the treatment of malignant lymphoma and Hodgkin's disease. , 1988, Seminars in hematology.
[12] B. Clarkson,et al. Non-Hodgkin's lymphomas: characteristics of long-term survivors following conservative treatment. , 1987, The American journal of medicine.
[13] Flavio Crippa,et al. Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] B. Clarkson,et al. Predictive model for prognosis in advanced diffuse histiocytic lymphoma. , 1986, Cancer research.
[15] E. Jaffe,et al. Twenty years of MOPP therapy for Hodgkin's disease. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] J. Bertino,et al. Pretreatment hematocrit as an independent prognostic variable in Hodgkin's disease. , 1986, Blood.
[17] A. Santoro,et al. Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. A report of 8-year results. , 1986, Annals of internal medicine.
[18] N. Geller,et al. Prognostic factors in advanced ovarian carcinoma. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] D. Deakin,et al. Factors affecting remission and survival in patients with advanced hodgkin's disease treated with MVPP , 1986, Hematological oncology.
[20] L. Specht,et al. Therapeutic implications of mediastinal involvement in advanced Hodgkin's disease. , 2009, Scandinavian journal of haematology.
[21] E. Gehan,et al. Chronic myelogenous leukemia: a multivariate analysis of the associations of patient characteristics and therapy with survival. , 1985, Blood.
[22] R. Priore,et al. Prognostic factors in patients with advanced stage prostate cancer. , 1985, Cancer research.
[23] J. Connors,et al. MOPP/ABV hybrid program: combination chemotherapy based on early introduction of seven effective drugs for advanced Hodgkin's disease. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] D. Johnston,et al. Prognostic factors for stage IV Hodgkin's disease treated with MOPP, with or without bleomycin , 1985, Cancer.
[25] D. Deakin,et al. The prognostic significance of mediastinal bulk in patients with stage IA-IVB Hodgkin's disease: a report from the Manchester Lymphoma Group. , 1985, Clinical radiology.
[26] A. Santoro,et al. Prognosis of bulky Hodgkin's disease treated with chemotherapy alone or combined with radiotherapy. , 1985, Cancer surveys.
[27] M. Tubiana,et al. Prognostic significance of erythrocyte sedimentation rate in clinical stages I-II of Hodgkin's disease. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] P. Biberfeld,et al. Prognostic factors in hodgkin's disease with special reference to age , 1984, Cancer.
[29] R. Mertelsmann,et al. Treatment of advanced Hodgkin's disease with chemotherapy and irradiation. Controlled trial of two versus three alternating, potentially non-cross-resistant drug combinations. , 1984, American Journal of Medicine.
[30] J. Earle,et al. Prognostic significance of mediastinal mass in adult Hodgkin's disease , 1984, Cancer.
[31] S. Rosenberg,et al. A dose and time response analysis of the treatment of Hodgkin's disease with MOPP chemotherapy. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] A. Santoro,et al. Alternating drug combinations in the treatment of advanced Hodgkin's disease. , 1982, The New England journal of medicine.
[33] S. Rosenberg,et al. The management of stage I--II Hodgkin's disease with irradiation alone or combined modality therapy: the Stanford experience. , 1982, Blood.
[34] C. Bloomfield,et al. Prognostic significance of mediastinal involvement in Hodgkin's disease treated with curative radiotherapy , 1980, Cancer.
[35] R. Dinsmore,et al. Fatal graft-versus-host disease following blood transfusion in Hodgkin's disease documented by HLA typing , 1980 .
[36] V. Devita,et al. Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute. , 1980, Annals of internal medicine.
[37] H. Gralnick,et al. American Burkitt's lymphoma: a clinicopathologic study of 30 cases. I. Clinical factors relating to prolonged survival. , 1975, The American journal of medicine.
[38] J. Bailar,et al. An exponential model relating censored survival data and concomitant information for prostatic cancer patients. , 1974, Journal of the National Cancer Institute.
[39] David R. Cox,et al. Regression models and life tables (with discussion , 1972 .
[40] L. Craver,et al. Report of the Nomenclature Committee , 1966 .
[41] N. Mantel. Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.
[42] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .